Born to Buy

Price Rationale

Final synthesis weights the four appraisers toward a midpoint between the comparable-sales view at 75 ETH, the liquidity-exit view at 60 ETH, and the cultural/cycle views near 90-92 ETH. Born to Buy is a 2018-12-31 SuperRare XCOPY OneOfOne with clean 1/1 provenance, but its only exact-token sale is the original onchain SuperRare sale for 1.25 ETH / $187.38 on 2019-01-03 from xcopy.eth to 0xdc19...6bc2, which remains both the last and highest exact sale. The packet has no current ask, no current best bid, no OTC sales, no grail flag, no grail reason names, and zero outgoing candidate benchmarks. That makes a grail-level or strongly validated 100+ ETH fair value too aggressive, while the early SuperRare date, XCOPY authorship, and later repricing across nearby early 1/1s support a value materially above the stale 2019 print. ETH/USD snapshot is null, so no current USD conversion is used.

What Caps The Price

A higher final value would need more token-specific support than the packet supplies: no live bid or ask, no OTC history, no post-2019 exact-token sale, no candidate benchmark set, and publicStanding.isGrail is false. Stronger nearby works such as Breaker, Afterglow, $LAVE, Chatbot and Chill?, and Right-click and Save As guy have fresher execution, higher public standing, or stronger benchmark context; those outcomes should not be imported mechanically into Born to Buy.

What Supports The Price

A lower final value would over-anchor to the 1.25 ETH / $187.38 January 2019 sale, which is strong provenance evidence but too stale to stand as 2026 value. Born to Buy is still an early SuperRare XCOPY 1/1 with a single-token supply and an on-brand consumer-death motif, and the supplied global context shows nearby early XCOPY 1/1s later clearing well above original low-single-digit prints, including 12 ETH, 29 ETH, 100 ETH, 128 ETH, and higher examples.